Title
Differences in COVID-19 Vaccine Concerns Among Asian Americans and Pacific Islanders: The COMPASS Survey.

Permalink
https://escholarship.org/uc/item/19s6q02d

Authors
Ta Park, Van
Dougan, Marcelle
Meyer, Oanh
et al.

Publication Date
2021-04-14

DOI
10.1007/s40615-021-01037-0

Peer reviewed
Differences in COVID-19 Vaccine Concerns Among Asian Americans and Pacific Islanders: The COMPASS Survey

Van Ta Park 1,2 & Marcelle Dougan 3 & Oanh Meyer 4 & Bora Nam 1 & Marian Tzuang 1 & Linda Park 1 & Quyen Vuong 5 & Janice Tsoh 2,6

Abstract

Background Understanding concerns for receiving COVID-19 vaccines is key to ensuring appropriately tailored health communications to increase vaccine uptake. However, limited data exists about vaccine concerns among Asian Americans and Pacific Islanders (AAPI).

Methods Data from the COVID-19 Effects on the Mental and Physical Health of AAPI Survey Study (COMPASS), a cross-sectional, national survey for AAPI adults in the U.S. were used (N=1,646). Descriptive statistics were used to assess sample characteristics including proportions of AAPI with various COVID-19 vaccine concerns, categorized as none, side-effects only, unsafe only, and multiple reasons, and differences in vaccine concerns by socio-demographics. Ordinary multivariable logistic regression analyses were conducted to evaluate associations between a characteristic and having any vaccine concerns.

Results Overall, 76% of the respondents reported having ≥1 concerns about the vaccine. The most common concern was side effects (65%). Vietnamese Americans reported less concerns (vs. Chinese Americans). Those who were 30-39 and 40-49 years old (vs. <30), females (vs. males), and experienced mild negative impacts from COVID-19 on family income/employment (vs. no change) reported more concerns about the vaccine. Those who had less vaccine concerns were those who reported higher (vs. low) health status, ≥60 years old (vs. <30), and separated/divorced/widowed (vs. single).

Discussion AAPI is a diverse population and this study revealed differences in vaccine concerns across AAPI groups. Findings revealed potential targets for patient education needs. Effective strategies to address various vaccine concerns across subgroups of AAPI will be crucial to ensure equity in vaccination uptake.

Keywords COVID-19 · vaccine concerns · Asian Americans · Pacific Islanders

Introduction

Addressing concerns regarding coronavirus disease 2019 (COVID-19) vaccination is a critical issue affecting the success of vaccination programs and bringing much needed control to the pandemic. Although a recent survey [1] found an increase in the proportion of US adults with greater degree of vaccine acceptance compared to early months of the pandemic [2, 3], a sizeable proportion of the US population is still unsure or do not plan to become vaccinated against COVID-19 [4]. The accelerated pace of vaccine development and the politicization of vaccine approval has heightened public anxieties and could have influenced its acceptance [5, 6].

It is essential that public health messages promoting COVID-19 vaccination target the underlying concerns especially for individuals who are among the vaccine “wait and see” group. This “wait and see group” is particularly important, given that they may be easier to convert from ambivalent
towards the vaccine to being willing to get it, compared to those who outright rejected to receive the vaccine. A recent poll by the Kaiser Family Foundation survey reported that 31% of the individuals surveyed belong to this group, saying that they will wait until the vaccine is available for a while and see how it is working for others who have taken it [4]. Several US studies have reported on specific concerns regarding the uptake of the COVID-19 vaccine including vaccine safety (i.e., side effects) [1–3, 7–9], vaccine effectiveness (including the need for more information about the vaccine) [2, 7], anti-vaccine beliefs and attitudes [1, 3], being worried about getting COVID-19 from the vaccine [1, 9], lack of trust [3], and perceived lack of testing [7].

A major gap in our understanding of concerns regarding COVID-19 vaccine is the scarcity of Asian Americans and Pacific Islander (AAPI) participation and thus their perspectives in these studies. To the authors’ knowledge, only two polls have surveyed Asian Americans about vaccine willingness, but the number of survey responses was few, and the respondents were limited to Asian Americans who could complete the surveys in English [10, 11]. Moreover, neither of the surveys were able to provide disaggregated AAPI data, which runs the risk of masking possible disparities across AAPI subgroups.

This study aimed to take a deeper dive to understand the different types of concerns related to COVID-19 vaccination and whether such concerns differ by characteristics between and within subgroups of the AAPI population using a large, ongoing multilingual survey called the COVID-19 Effects on the Mental and Physical Health of AAPI Survey Study (COMPASS). The authors recognize that surveys such as this one are conducted in the context of a highly dynamic and changing landscape. However, given growing reports of inequalities in COVID-19 infection and mortality among AAPI [12–14], it is important to shed light on COVID-19 vaccine concerns specific to AAPI, especially when these may become barriers and/or facilitators to vaccination efforts that lead to achievement of herd immunity against COVID-19.

Methods

Study Eligibility, Recruitment, and Procedures

COMPASS is a cross-sectional, community-based national survey that assesses the COVID-19 effects on AAPI. To be eligible, participants must self-identify as AAPI alone or in combination with other races/ethnicities; be able to read English/Chinese (traditional or simplified Chinese)/Korean/Vietnamese; be ≥ 18 years old; and reside in the USA. The survey is available online (https://compass.ucsf.edu/) with as needed survey administration assistance by phone in the above-mentioned languages. COMPASS is an ongoing survey study, and this paper reports on 1646 participants who completed the survey from October 24–December 11, 2020, which was selected as the cutoff date for this analysis since it was the first day that the FDA authorized a COVID-19 vaccine [15]. The mean survey completion time was 21.6 (standard deviation (SD) = 15.5) min. Each participant was provided an option of receiving a $10 gift card upon survey completion.

Participants heard about COMPASS through community partners who serve AAPI, personal/professional networks, social media, email/listservs, flyers, and ethnic media. COMPASS also leveraged the Collaborative Approach for AAPI Research and Education (CARE) Registry [16] to recruit participants by email announcements. After providing e-informed consent (n = 1535) or verbal consent via phone (n = 111), 1646 participants completed the COVID-19 survey. The survey used Research Electronic Data Capture (REDCap) tools hosted at the University of California, San Francisco (UCSF) [17, 18].

Measures

Dependent Variable

COVID-19 Vaccine Concerns [19] were assessed with the following question: “Some people may have concerns about COVID-19 vaccines, do you have any of the concerns below (please check all that apply)?” Response options included: (1) I do not have any concerns; (2) I’m concerned about potential side effects; (3) I think COVID-19 vaccine may not be safe; (4) I do not think that COVID-19 is dangerous to my health; (5) I am against vaccination in general; (6) The best way is for nature to take its course; (7) I believe natural or traditional remedies; (8) I’m afraid of injections; (9) Religious reasons; and (10) Others (please describe). The survey also elicited vaccine concerns via open-ended questions.

Independent Variables

Socio-demographic items were drawn from CARE [16]. Variables included race, cultural group, sex, sexual orientation, year of birth, nativity, years lived in the USA, marital status, employment, education, and annual household income in 2019. Participants were asked how well they could speak/read/write English.

Participants completed several existing surveys related to COVID-19 including the Coronavirus Impact Scale (CIS) related to changes in family income/employment [20] and COVID-19 status [21] (yes, no, unsure diagnosis).

Participants answered duration of Shelter-in-Place (SIP) questions based on region, per the Census Bureau’s definition of region (Midwest/Northeast/South/West) [22] which was obtained by converting the zip code, or Internet protocol
address in the case of missing zip codes \((n = 188)\). SIP and Perceived Severity of COVID-19 items were developed by COMPASS.

General health was measured by asking participants to indicate their health “today” on a scale from 0 (worst) to 100 (the best health you can imagine) using the EQ-5D [23, 24] item, which was categorized into quintiles.

Translation Process

The World Health Organization’s process of translation and adaptation of instruments [25] was used to guide the translations of the study materials that were not already available in the targeted language(s).

Statistical Analysis

The outcome variable, vaccine concerns, was examined in two ways: (1) concerns (none/any), unsafe (yes/no), side effects (yes/no), and number of concerns, and hypothesized factors associated with vaccine concerns, specifically race, ethnic group, sex, sexual orientation, age, nativity, marital status, employment, education, household income, length of shelter in place, perceived severity of COVID-19, effect of coronavirus on family income, region, and general health status. Participants who responded that they could speak/read/write English less than very well (“some,” “a little bit,” or “not at all”) were categorized as having limited English proficiency (LEP) [26]. This study used binary logistic regressions to model the association between having vaccine concerns (none/any) and these same factors. Variables that attained a \(p\) value of < 0.10 in bivariate logistic regression analyses were included in the final model. All statistical tests were two-sided. Hosmer-Lemeshow goodness of fit test [27] indicated an acceptable fit of the final model \((P = 0.18)\). Statistical analyses were conducted using SAS Software [28].

Open-ended responses were analyzed by a line-by-line reading of the data and then categorized into major codes and then themes with accompanying illustrative quotes. The analysis was done by one of the lead investigators with prior experience in qualitative analysis.

Human Subject Protection

This study was approved by UCSF’s Institutional Review Board (protocol 20-31925).

Results

Sample Characteristics

Sample characteristics \((N = 1646)\) are shown in Table 1. Participants included 97.6% Asian Americans and 2.4% Native Hawaiians and Pacific Islanders (NHPI). The major cultural groups included ethnic Chinese (including persons from Hong Kong and Taiwan; 37.1%), Vietnamese (29.0%), and Korean (20.5%). The sample comprised of more females (62.5%) and mostly heterosexuals (90.0%). The mean age of participants was 40.6 years (SD: 15.8) and ranged from 18 to 88. Overall, 61.5% of participants were foreign-born who had lived in the USA an average of 22.8 years (SD: 13.6), and 20% had limited English proficiency. Many completed the survey in English (73.3%).

COVID-19 Impacts

More than 64% reported that the COVID-19 had impacted their family income and employment (Table 1). Over half (52.1%) indicated their SIP was 3 months or longer; 45.0% perceived the COVID-19 severity of where they lived was “somewhat” to “a lot” more than other US areas. Approximately, two-thirds of participants reported mild to severe impact on family income and employment due to the COVID-19. Few (2.0%) said they had tested positive for COVID-19.

COVID-19 Vaccine Concerns and Willingness

As shown in Table 1, about 24% reported no vaccine concerns. One in three (34.1%) were only concerned about side effects, 6.0% were only concerned about vaccine safety, and 36.4% reported multiple concerns. Figure 1 shows the number of concerns about COVID-19 vaccine by willingness to get the vaccine. Among the 725 participants who said they would definitely get the vaccine, 323 of them (44.6%) said they had no concerns about the vaccine compared to 113 (15.6%) who had two or more concerns. Among the 41 participants who said they definitely would not get the vaccine, 3 of them (7.3%) had no concerns compared with 25 (61.0%) who had two or more concerns.

Regarding the type of concerns (Fig. 2), 249 (34.3%) of those who said they would definitely get the vaccine were concerned only about side effects, 17 (2.3%) were concerned only about the vaccine being unsafe, and 139 (19.2%) were had multiple concerns. Among those who said they definitely would not get the vaccine, 3 (7.3%) were concerned only about side effects, 6 (14.63%) were concerned that only that the vaccine was unsafe, and 29 (70.7%) had multiple concerns.
### Table 1  COMPASS study sample characteristics and COVID-19 vaccine concerns (N = 1646)

| N   | %    |
|-----|------|
| COVID-19 vaccine concerns |       |
| None | 386  | 23.5 |
| Side effects only | 562  | 34.1 |
| Unsafe only | 99   | 6.0  |
| Multiple reasons | 599  | 36.4 |
| Number of COVID-19 vaccine concerns |       |
| None | 391  | 23.8 |
| One | 723  | 43.9 |
| Two or more | 532  | 32.3 |
| Race |       |
| Asian | 1607 | 97.6 |
| Native Hawaiians and Pacific Islanders | 39  | 2.4  |
| Cultural group |       |
| Asian Indian | 28   | 1.7  |
| Ethnic Chinese¹ | 611  | 37.1 |
| Filipino | 71   | 4.3  |
| Japanese | 29   | 1.8  |
| Korean | 337  | 20.5 |
| Native Hawaiian | 17   | 1.0  |
| Samoan | 13   | 0.8  |
| Vietnamese | 477  | 29.0 |
| Others/mixed | 63   | 3.9  |
| Sex |       |
| Female | 1,028 | 62.5 |
| Male | 601  | 36.5 |
| Others/decline to state² | 17   | 1.0  |
| Sexual orientation |       |
| Heterosexual | 1,478 | 90.0 |
| Not heterosexual | 95   | 5.8  |
| Decline to State | 69   | 4.2  |
| Age (in years) |       |
| 40.6 (15.8)³; range: 18–88 |       |
| < 30 | 535  | 32.5 |
| 30–39 | 339  | 20.6 |
| 40–49 | 237  | 14.4 |
| 50–59 | 295  | 17.9 |
| > 60 | 240  | 14.6 |
| Nativity |       |
| US-born | 619  | 37.6 |
| Foreign-born | 1,012 | 61.5 |
| Years in the USA | 22.8 (13.6)³; range: 0–83 |       |
| Don’t know | 15   | 0.9  |
| Limited English proficiency (LEP)⁴ |       |
| Yes | 335  | 20.4 |
| No | 1311 | 79.7 |
| Marital status |       |
| Single | 564  | 34.3 |
| Married/living with partner | 988  | 60.0 |

### Table 1 (continued)

| N   | %    |
|-----|------|
| Separated/divorced/widowed | 83   | 5.0  |
| Declined | 11   | 0.7  |
| Employment status |       |
| Full-time | 735  | 44.7 |
| Part-time | 287  | 17.4 |
| Homemaker | 150  | 9.1  |
| Unemployed | 213  | 12.9 |
| Retired | 141  | 8.6  |
| Others/decline to state | 120  | 7.3  |
| Annual household income in 2019 ($) |       |
| ≤ 25,000 | 283  | 17.2 |
| > 25,000–75,000 | 530  | 32.2 |
| > 75,000–150,000 | 408  | 24.8 |
| > 150,000 | 258  | 15.7 |
| Decline to state | 167  | 10.2 |
| Tested positive for COVID-19 |       |
| Yes | 33   | 2.0  |
| No | 1485 | 90.2 |
| Not sure | 108  | 6.7  |
| Missing | 20   | 1.2  |
| Willing to get COVID-19 vaccine |       |
| Definitely yes | 725  | 44.0 |
| Probably yes | 503  | 30.6 |
| Unsure | 295  | 17.9 |
| Probably no | 82   | 5.0  |
| No | 41   | 2.5  |
| Length of SIP ⁵ Order |       |
| No order | 93   | 5.7  |
| < 1 month | 111  | 6.8  |
| 1 to <2 months | 227  | 13.8 |
| 2 to <3 months | 223  | 13.6 |
| 3 months or longer | 855  | 52.1 |
| Do not know | 132  | 8.0  |
| The severity of COVID where you live |       |
| A lot less | 146  | 8.9  |
| Somewhat less | 338  | 20.6 |
| About the same | 417  | 25.4 |
| Somewhat more | 502  | 30.6 |
| A lot more | 236  | 14.4 |
| COVID-19 effect on family income/employment |       |
| No change | 587  | 35.9 |
| Mild | 554  | 33.9 |
| Moderate | 439  | 26.8 |
| Severe | 56   | 3.4  |
Multivariable Analyses

In the multivariable models (Table 3), cultural group was associated with vaccine concerns, with Vietnamese significantly less likely to have any concerns about the vaccine compared to ethnic Chinese: adjusted odds ratio (aOR) 0.60 [95% CI 0.43–0.82], P < .01. The difference for other cultural groups was not statistically significant relative to ethnic Chinese (reference group). When changing the reference group to Vietnamese in post-hoc analyses, Filipinos and Koreans were significantly more likely than Vietnamese to have any concerns about the vaccine, aOR 3.42 [95% CI 1.48–7.92], P < .01) and 1.64 [95% CI 1.13–2.39], P = .01), respectively (data not shown).

Age was also associated with having any vaccine concerns: compared to those less than 30 years of age, those 30–39 years of age and those 40–49 years of age were significantly more likely to have any vaccine concerns: aOR 2.03 [95% CI 1.31–3.15], P < .01) and 1.69 [95% CI 1.03–2.78], P = .04, respectively. All other age groups were not significant relative to those less than 30 years of age (reference group).

Sex was associated with concerns about the vaccine, with males significantly less likely to have any concerns compared to females, with an aOR of 0.52 [95% CI 0.41–0.68], P < .01). Self-reported health status was also a significant correlate of having vaccine concerns. Most of those who had higher self-reported health were significantly less likely to have vaccine concerns (a0Rs ranged from 0.53 to 0.58). Marital status was associated with vaccine concerns, with those separated, divorced, or widowed significantly less likely to have any concerns about the vaccine compared to those who were single: aOR 0.33 [95% CI 0.18–0.61], P < .01). Income and LEP were not associated with having any vaccine concerns in the

Bivariate Analyses

In bivariate analyses (Table 2), cultural group, sex, age, LEP, marital status, income, COVID-19 effect on family income/employment, census regions, and self-reported health status were significantly associated with concerns about the COVID-19 vaccine. On the other hand, race, sexual orientation, nativity, employment status, education, caregiver status, length of SIP order, and COVID-19 severity region were not.
Table 2  Concerns about COVID-19 vaccines by participant characteristics (N = 1646)

| Concerns about COVID-19 vaccines by participant characteristics (N = 1646) | Unsafe | Side effects | Number of concerns |
|---|---|---|---|
| | Yes (n = 544) (%) | No (n = 1102) (%) | Yes (n = 1070) (%) | No (n = 576) (%) | None (n = 391) (%) | One (n = 723) (%) | Two or more (n = 532) (%) |
| Race | | | | | | | |
| Asian | 532 (33.1) | 1075 (66.9) | 1050 (65.3) | 557 (34.7) | 383 (23.8) | 705 (43.9) | 519 (32.3) |
| NHPI† | 12 (30.8) | 27 (69.2) | 20 (51.3) | 19 (48.7) | 8 (20.5) | 18 (46.2) | 13 (33.3) |
| Cultural group | | | | | | | |
| Ethnic Chinese² | 215 (35.2) | 396 (64.8) | 418 (68.4) | 193 (31.6) | 127 (20.8) | 274 (44.8) | 210 (34.4) |
| Filipino | 21 (29.6) | 50 (70.4) | 60 (84.5) | 11 (15.5) | 7 (9.86) | 40 (56.3) | 24 (33.8) |
| Korean | 131 (38.8) | 206 (61.1) | 213 (63.2) | 124 (36.8) | 70 (20.8) | 159 (47.2) | 108 (32.0) |
| Vietnamese | 125 (26.2) | 352 (73.8) | 282 (59.1) | 195 (40.9) | 152 (31.9) | 190 (39.8) | 135 (28.3) |
| Others | 52 (34.7) | 98 (65.3) | 97 (64.7) | 53 (35.3) | 35 (23.3) | 60 (40.0) | 55 (36.7) |
| P value | 0.864 | 0.889 | | | | | |
| Sex | | | | | | | |
| Female | 347 (33.8) | 681 (66.2) | 715 (69.6) | 313 (30.4) | 296 (20.0) | 470 (45.7) | 352 (34.2) |
| Male | 193 (32.1) | 408 (67.9) | 342 (56.9) | 259 (43.1) | 182 (30.3) | 245 (40.8) | 174 (28.9) |
| Others/decline³ | 4 (23.5) | 13 (76.5) | 13 (76.5) | 4 (23.5) | 3 (17.6) | 8 (47.1) | 6 (35.3) |
| P value | < .01 | < .001 | | | | | |
| Sexual orientation | | | | | | | |
| Heterosexual | 497 (33.6) | 981 (66.4) | 955 (64.6) | 523 (35.4) | 355 (24.0) | 639 (43.2) | 484 (32.8) |
| Not heterosexual | 26 (27.4) | 69 (72.6) | 63 (66.3) | 32 (33.7) | 22 (23.1) | 45 (47.4) | 28 (29.5) |
| Decline to state | 19 (27.5) | 50 (72.5) | 49 (71.0) | 20 (29.0) | 14 (20.3) | 38 (55.1) | 17 (24.6) |
| P value | 0.558 | < .001 | | | | | |
| Age (in years) | | | | | | | |
| < 30 | 191 (35.7) | 344 (64.3) | 364 (68.0) | 171 (32.0) | 128 (23.9) | 220 (41.1) | 187 (35.0) |
| 30–39 | 124 (36.6) | 215 (63.4) | 230 (67.9) | 109 (32.1) | 62 (18.3) | 157 (46.3) | 120 (35.4) |
| 40–49 | 86 (36.3) | 151 (63.7) | 158 (66.7) | 79 (33.3) | 49 (20.7) | 107 (45.2) | 81 (34.2) |
| 50–59 | 88 (29.8) | 207 (70.2) | 190 (64.4) | 105 (35.6) | 66 (22.4) | 140 (47.5) | 89 (30.2) |
| > 60 | 55 (22.9) | 185 (77.1) | 128 (53.3) | 112 (46.7) | 86 (35.8) | 99 (41.3) | 55 (22.9) |
| P value | < .001 | < .001 | | | | | |
| Nativity | | | | | | | |
| Foreign-born | 323 (31.9) | 689 (68.1) | 649 (64.1) | 363 (35.9) | 249 (24.6) | 445 (44.0) | 318 (31.4) |
| US-born | 217 (35.1) | 402 (64.9) | 411 (66.4) | 208 (33.6) | 139 (22.5) | 272 (43.9) | 208 (33.6) |
| Don’t know | 4 (26.7) | 11 (73.3) | 10 (66.7) | 5 (33.3) | 3 (20.0) | 6 (40.0) | 6 (40.0) |
| P value | 0.370 | 0.642 | 0.785 | | | | |
| LEP⁴ | | | | | | | |
| Yes | 102 (30.5) | 233 (69.5) | 187 (55.8) | 184 (44.2) | 100 (29.8) | 138 (41.2) | 97 (29.0) |
| No | 442 (33.7) | 869 (66.3) | 883 (67.4) | 428 (32.6) | 291 (22.2) | 585 (44.6) | 435 (33.2) |
| P value | 0.257 | < .001 | | | | | |
| Marital status | | | | | | | |
| Single | 196 (34.7) | 368 (65.3) | 382 (67.7) | 182 (32.3) | 123 (21.8) | 252 (44.7) | 189 (33.5) |
| Married/living with partner | 322 (32.6) | 666 (67.4) | 633 (64.1) | 355 (35.9) | 235 (23.8) | 442 (44.7) | 311 (31.5) |
| Separated/divorced/widowed | 22 (26.5) | 61 (73.5) | 46 (55.4) | 37 (44.6) | 32 (38.6) | 23 (27.7) | 28 (33.7) |
| Declined | 4 (36.4) | 7 (63.6) | 9 (81.8) | 2 (18.2) | 1 (9.1) | 6 (54.5) | 4 (36.4) |
| P value | 0.477 | 0.074 | | | | | |
| Employment status | | | | | | | |
| Full-time | 251 (34.1) | 484 (65.9) | 476 (64.8) | 259 (35.2) | 165 (22.5) | 325 (44.2) | 245 (33.3) |
| Part-time | 95 (33.1) | 192 (66.9) | 184 (64.1) | 103 (35.9) | 65 (22.7) | 135 (47.0) | 87 (30.3) |
Table 2 (continued)

| Unsafe Side effects | Number of concerns |
|---------------------|--------------------|
| Yes n = 544 (%)     | Yes n = 1070 (%)   | None n = 391 (%) |
| No n = 1102 (%)     | No n = 576 (%)     | One n = 723 (%)  |
|                     |                    | Two or more n = 532 (%) |
| Homemaker           |                    |                      |
| Yes                 | 54 (36.0)         | 100 (66.7)           | 33 (22.0) |
|                     | 96 (64.0)         | 50 (33.3)            | 67 (44.7) |
| No                  | 1102 (%)          | 1170 (61.0)          | 55 (25.8) |
|                     | 148 (69.5)        | 66 (31.0)            | 86 (40.4) |
| Retired             |                    |                      |
| Yes                 | 39 (27.7)         | 84 (59.6)            | 45 (31.9) |
|                     | 102 (72.3)        | 57 (40.4)            | 59 (41.8) |
| No                  | 40 (33.3)         | 79 (65.8)            | 28 (22.3) |
|                     | 80 (66.7)         | 41 (34.2)            | 51 (42.5) |
| Others/declined     |                    |                      |
| Yes                 | 40 (33.3)         | 72 (61.3)            | 34 (23.9) |
|                     | 80 (66.7)         | 55 (38.7)            | 58 (40.9) |
| P value             | 0.629             | 0.598                | 0.512     |
| Education           |                    |                      |
| High school or less |                    |                      |
| Yes                 | 69 (27.9)         | 160 (64.8)           | 57 (23.1) |
|                     | 178 (72.1)        | 87 (35.2)            | 120 (48.6) |
| No                  | 73 (30.7)         | 147 (61.8)           | 68 (28.6) |
|                     | 165 (69.3)        | 91 (38.2)            | 101 (42.4) |
| Bachelor’s degree   |                    |                      |
| Yes                 | 226 (35.7)        | 422 (66.7)           | 147 (23.2) |
|                     | 407 (64.3)        | 211 (33.3)           | 262 (41.4) |
| No                  | 171 (33.7)        | 325 (64.1)           | 115 (22.7) |
|                     | 336 (66.3)        | 182 (35.9)           | 229 (45.2) |
| P value             | 0.131             | 0.565                | 0.174     |
| Annual household income in 2019 ($) |        |                      |
| ≤ 25,000            | 544 (%)           | 1102 (%)             | 391 (%) |
| > 25,000–75,000     | 1070 (%)          | 576 (%)              | 723 (%) |
| > 75,000–150,000    | 532 (%)           | 532 (%)              | 532 (%) |
| > 150,000           | 391 (%)           | 391 (%)              | 391 (%) |
| Decline to state    |                    |                      |
| Yes                 | 114 (32.1)        | 234 (65.9)           | 84 (23.7) |
|                     | 241 (67.9)        | 121 (34.1)           | 156 (43.9) |
| No                  | 430 (33.3)        | 836 (64.8)           | 307 (23.8) |
|                     | 861 (66.7)        | 455 (35.2)           | 567 (43.9) |
| P value             | 0.671             | 0.685                | 0.999     |
| Caregiver           |                    |                      |
| Yes                 | 114 (32.1)        | 234 (65.9)           | 84 (23.7) |
|                     | 241 (67.9)        | 121 (34.1)           | 156 (43.9) |
| No                  | 430 (33.3)        | 836 (64.8)           | 307 (23.8) |
|                     | 861 (66.7)        | 455 (35.2)           | 567 (43.9) |
| P value             | 0.671             | 0.685                | 0.999     |
| Length of SIP order |                    |                      |
| No order            | 29 (31.2)         | 63 (67.7)            | 22 (23.7) |
|                     | 64 (69.8)         | 30 (23.2)            | 43 (46.2) |
| < 1 month           | 25 (22.5)         | 67 (60.4)            | 29 (26.1) |
|                     | 86 (77.5)         | 44 (39.6)            | 59 (53.2) |
| 1 to < 2 months     | 82 (36.1)         | 150 (66.1)           | 54 (23.8) |
|                     | 143 (63.9)        | 77 (33.9)            | 93 (41.0) |
| 2 to < 3 months     | 72 (32.3)         | 148 (66.4)           | 48 (21.5) |
|                     | 151 (67.7)        | 75 (33.6)            | 99 (43.4) |
| 3 months or longer  | 289 (33.8)        | 555 (64.9)           | 204 (23.9) |
|                     | 566 (66.2)        | 300 (35.1)           | 369 (43.1) |
| Don’t know          | 45 (34.1)         | 85 (64.4)            | 32 (24.2) |
|                     | 87 (65.9)         | 47 (35.6)            | 58 (43.9) |
| P value             | 0.215             | 0.892                | 0.506     |
| Severity of COVID-19 where you live |        |                      |
| A lot less          | 48 (32.9)         | 104 (71.2)           | 31 (21.2) |
|                     | 98 (67.1)         | 42 (28.8)            | 60 (41.1) |
| Somewhat less       | 104 (30.8)        | 222 (65.7)           | 73 (21.6) |
|                     | 234 (69.2)        | 116 (34.3)           | 166 (49.1) |
| About the same      | 144 (34.5)        | 271 (65.0)           | 111 (20.0) |
|                     | 273 (65.5)        | 146 (35.0)           | 187 (44.8) |
| Somewhat more       | 159 (31.7)        | 316 (63.0)           | 134 (26.7) |
|                     | 343 (68.3)        | 186 (37.0)           | 208 (41.4) |
| A lot more          | 87 (36.9)         | 151 (64.0)           | 57 (24.2) |
|                     | 149 (63.1)        | 85 (36.0)            | 98 (41.5) |
| P value             | 0.526             | 0.464                | 0.337     |
| COVID-19 effect on family income/employment |        |                      |
| No change           | 178 (30.3)        | 364 (62.0)           | 157 (26.8) |
|                     | 409 (69.7)        | 223 (38.0)           | 255 (43.4) |
| Mild                | 185 (33.4)        | 381 (68.8)           | 111 (20.0) |
|                     | 369 (66.6)        | 173 (31.2)           | 262 (47.3) |
| Moderate            | 154 (35.1)        | 287 (65.4)           | 110 (25.1) |
|                     | 285 (64.9)        | 152 (34.6)           | 175 (39.9) |
| Severe              | 21 (37.5)         | 31 (55.4)            | 11 (19.6) |
|                     | 35 (62.5)         | 25 (44.6)            | 28 (50.0) |
| P value             | 0.347             | < .05                | 0.062     |
| Census region       |                    |                      |
| Midwest             | 24 (26.7)         | 64 (71.1)            | 22 (24.4) |
|                     | 66 (73.3)         | 26 (28.9)            | 40 (44.4) |
| Northeast           | 57 (40.1)         | 87 (61.3)            | 34 (23.9) |
|                     | 85 (59.9)         | 55 (38.7)            | 58 (40.9) |

J. Racial and Ethnic Health Disparities
final model. Finally, respondents reported experiencing mild negative effect on family income/employment due to COVID-19 were more likely to report vaccine concerns when compared to those experiencing no change.

**Open-Ended Response Analysis**

A thematic analysis of the 61 open-ended responses revealed five major themes including (1) vaccine trial done too quickly; (2) distrust of government involvement in trial; (3) worry about side/long-term effects; (4) concerns about efficacy and effectiveness; and (5) appropriateness for own body/self. Table 4 shows sample quotes that illustrate each of the theme. Concerns about safety and distrust of how rapidly the vaccine trial was completed were quite salient. Other issues raised included concerns about cost and lack of equitable distribution of the vaccine.

**Discussion**

The findings from this COMPASS national survey are among the first to focus on the AAPI population and concerns related to the COVID-19 vaccine right before the first vaccine became available in December 2020. Overall, 76% of the 1646 respondents reported having at least one or more concerns about the vaccine. The most common concern was side effects (65%). We found several characteristics that reflect subpopulations who expressed more or less concerns with receiving the vaccine. In particular, the subgroups who had significant vaccine concerns included those who were 30–39 and 40–49 age group and females. Respondents who indicated experiencing mild negative impacts from COVID-19 on family income also reported more concerns than those reported no change in income. Those who had less vaccine concerns were those who reported the higher health status compared to those who reported the low health status. In addition, those who were aged 60 and older compared to those who were younger than 30 years old or those who were separated, divorced, or widowed had less vaccine concerns than those who reported being single. In addition, Vietnamese American also reported less concerns when compared to Chinese, Filipino, and Korean Americans.

The COMPASS survey included 62.5% female respondents with 53.1% respondents being between 18 and 39 years of age. Female respondents had significantly more concerns about the vaccine compared to male respondents, which was consistent to findings from a US opinion survey [29]. Since the effects may potentially be additive, these findings may have potential implications for women of child-bearing age though there is limited research on the effects of the COVID-19 vaccine in pregnancy. The Centers for Disease Control and Prevention (CDC) and the Independent Advisory Committee on Immunization Practices (ACIP) recommends that people who are pregnant may choose to be vaccinated and should make an informed decision after discussion with their healthcare provider [30]. Those who are pregnant are at increased risk of severe illness from COVID-

---

1 Native Hawaiian and Pacific Islanders
2 Ethnic Chinese includes mainland Chinese, Hongkonger, Taiwanese, and Huaren
3 Others: n = 7; decline: n = 6
4 English proficiency categorized as limited if speaking or writing or reading English indicated as “some,” “a little,” or “not at all”
5 SIP shelter-in-place

---

Table 2 (continued)

| Safeguards | Unsafe | Side effects | Number of concerns |
|------------|--------|--------------|-------------------|
| Yes        | n = 544 (%) | Yes | n = 1070 (%) | No | n = 576 (%) | None | n = 391 (%) | One | n = 723 (%) | Two or more | n = 532 (%) |
| South      | 119 (39.0) | 184 (60.3) | 121 (39.7) | 76 (24.9) | 126 (41.3) | 103 (33.8) |
| West       | 344 (31.0) | 735 (66.3) | 374 (33.7) | 259 (23.3) | 499 (45.0) | 351 (31.7) |
| P value    | < .01 | 0.108 | 0.910 |

Self-reported health, quintiles

| Quintile 1 (lowest) | South | West | P value |
|---------------------|-------|------|---------|
| Yes                 | 120 (34.8) | 225 (65.2) | < .05 |
| No                  | 239 (69.3) | 106 (30.7) | < .01 |
| P value             | 64 (18.6) | 166 (48.1) | 0.108 |
| Quintile 2          | South | West | P value |
| Yes                 | 93 (35.2) | 171 (64.8) | < .05 |
| No                  | 172 (65.2) | 92 (34.8) | < .05 |
| P value             | 65 (24.6) | 107 (40.5) | 0.910 |
| Quintile 3          | South | West | P value |
| Yes                 | 116 (35.8) | 208 (64.2) | < .01 |
| No                  | 225 (69.4) | 99 (30.5) | < .01 |
| P value             | 73 (22.5) | 134 (41.4) | < .05 |
| Quintile 4          | South | West | P value |
| Yes                 | 109 (31.0) | 242 (69.0) | < .01 |
| No                  | 217 (61.8) | 134 (38.2) | < .01 |
| P value             | 92 (26.2) | 151 (43.0) | < .01 |
| Quintile 5 (highest)| South | West | P value |
| Yes                 | 77 (28.5) | 193 (71.5) | < .05 |
| No                  | 162 (60.0) | 108 (40.0) | < .01 |
| P value             | 76 (28.2) | 120 (44.4) | < .01 |

---

1 Native Hawaiian and Pacific Islanders
2 Ethnic Chinese includes mainland Chinese, Hongkonger, Taiwanese, and Huaren
3 Others: n = 7; decline: n = 6
4 English proficiency categorized as limited if speaking or writing or reading English indicated as “some,” “a little,” or “not at all”
5 SIP shelter-in-place
Table 3 Crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for COVID-19 vaccine concerns

| Characteristics                  | N       | Crude OR        | Adjusted OR1 |
|----------------------------------|---------|-----------------|--------------|
| **Race**                         |         |                 |              |
| Asian                            | 1607    | Reference       | N/A          |
| NHPI1                            | 39      | 1.19 (0.54–2.62)|              |
| **Cultural group**               |         |                 |              |
| Ethnic Chinese3                   | 524     | Reference       | Reference    |
| Filipino                         | 71      | 2.38 (1.06–5.31)| 2.04 (0.89–4.68)|
| Korean                           | 337     | 0.99 (0.71–1.38)| 0.97 (0.67–1.41)|
| Vietnamese                       | 478     | 0.58 (0.44–0.76)| 0.60 (0.44–0.83)|
| Others/mixed                     | 307     | 0.85 (0.56–1.31)| 0.79 (0.50–1.25)|
| **Sex**                          |         |                 |              |
| Female                           | 1028    | Reference       | Reference    |
| Male                             | 601     | 0.56 (0.45–0.71)| 0.52 (0.40–0.67)|
| **Sexual orientation**           |         |                 |              |
| Heterosexual                     | 1478    | Reference       | N/A          |
| Non-heterosexual                 | 95      | 1.03 (0.63–1.68)|              |
| **Age, years**                   |         |                 |              |
| < 30                             | 535     | Reference       | Reference    |
| 30–39                            | 339     | 1.42 (1.01–2.00)| 2.05 (1.32–3.18)|
| 40–49                            | 237     | 1.19 (0.82–1.73)| 1.72 (1.05–2.82)|
| 50–59                            | 295     | 1.15 (0.81–1.61)| 1.56 (0.98–2.49)|
| ≥ 60                             | 240     | 0.56 (0.40–0.78)| 0.99 (0.61–1.60)|
| **Nativity**                     |         |                 |              |
| US-born                          | 1012    | Reference       | Reference    |
| Foreign-born                     | 619     | 0.90 (0.71–1.14)|              |
| **LEP4**                         |         |                 |              |
| Yes                              | 335     | 0.72 (0.55–0.96)| 0.81 (0.56–1.17)|
| No                               | 1311    | Reference       | Reference    |
| **Marital status**               |         |                 |              |
| Single                           | 564     | Reference       | Reference    |
| Married/living with partner      | 988     | 0.91 (0.71–1.16)| 0.82 (0.56–1.20)|
| Separated/divorced/widowed       | 83      | 0.44 (0.27–0.72)| 0.33 (0.18–0.62)|
| **Employment status**            |         |                 |              |
| Full-time                        | 735     | Reference       | N/A          |
| Part-time                        | 287     | 1.00 (0.72–1.39)|              |
| Homemaker                        | 150     | 1.10 (0.72–1.70)|              |
| Unemployed                       | 213     | 0.87 (0.61–1.24)|              |
| Retired                          | 141     | 0.61 (0.41–0.91)|              |
| Others/declined                  | 120     | 0.90 (0.57–1.42)|              |
| **Education**                    |         |                 |              |
| ≤ High school                    | 247     | Reference       | N/A          |
| Some college or technical        | 238     | 0.73 (0.48–1.10)|              |
| Bachelor’s degree                | 633     | 0.96 (0.67–1.36)|              |
| ≥ Master’s degree                | 507     | 0.99 (0.69–1.42)|              |
| **Household income ($)**         |         |                 |              |
| ≤ 25,000                         | 283     | Reference       | Reference    |
| > 25,000–75,000                  | 530     | 1.49 (1.08–2.05)| 1.19 (0.82–1.73)|
| >75,000–150,000                  | 408     | 1.60 (1.14–2.25)| 1.07 (0.7–1.62)|
| > 150,000 +                      | 127     | 1.55 (1.05–2.27)| 0.97 (0.59–1.6)|
| **Length of SIP5 order**         |         |                 |              |
| No order                         | 93      | Reference       | N/A          |
| < 1 month                        | 111     | 1.14 (0.60–2.16)|              |
| 1 ≤ 2 months                     | 227     | 0.94 (0.53–1.66)|              |
| 2 ≤ 3 months                     | 223     | 0.91 (0.51–1.61)|              |
19; therefore, a personalized discussion is warranted about their likelihood of exposure and potential risk to them and their fetuses if they are infected [30]. However, there are currently limited data on the safety of the COVID-19 vaccines from animal development and reproductive toxicity studies; additional studies are currently underway in those who are pregnant [30].

The findings that Vietnamese Americans had less concerns about the COVID-19 vaccine are consistent with our finding of more willingness to receive the COVID-19 vaccine in this cultural group (vs. Chinese Americans) (under review) [31]. The previously reported findings were consistent with a global online survey that found that Vietnamese Americans were significantly more willing to receive the COVID-19 vaccine (vs. Chinese Americans) [32]. There is limited research on the potential reasons for these differences as this paper is among the first to demonstrate that AAPI groups are heterogeneous in their concerns about the COVID-19 vaccine. The differences between cultural group could not be explained by the variables examined such as demographics or impacts from COVID-19; thus informative qualitative research will be helpful to elucidate these findings.

One novel finding is that vaccine concern was associated with the experience of mild negative impact of COVID-19 on family income when compared to those experienced no impact. This association has not been reported in prior studies with the English-speaking and/or the general US population. Demographics or other individual factors examined could not explain the association. In bivariate analyses, it appeared that those with mild negative impact on family income tended to experience more concerns side effects. Future research is warranted to understand if and how impacts from COVID-19 are associated with vaccine concern.

Similar to prior research, hesitancy about getting the COVID-19 vaccine had to do with safety [33, 34]. Participants in the current study felt that vaccine trials were done too quickly and had concerns about efficacy. Given how long vaccines had taken in the past, from viral sampling to approval, it was highly optimistic that a COVID-19 vaccine would be developed by the summer of 2021 (Ball, 2020).

### Table 3 (continued)

| Characteristics                              | N    | Crude OR          | Adjusted OR |
|----------------------------------------------|------|-------------------|-------------|
| ≥ 3 months                                   | 855  | 0.99 (0.60–1.64)  |             |
| P value                                      |      | 0.97              |             |
| Severity of COVID-19                         |      |                   |             |
| A lot less                                   | 146  | 0.94 (0.59–1.49)  | N/A         |
| Somewhat less                                | 338  | 0.96 (0.68–1.36)  |             |
| About the same                               | 417  | Reference         |             |
| Somewhat more                                | 502  | 1.24 (0.92–1.69)  |             |
| A lot more                                   | 236  | 1.08 (0.74–1.58)  |             |
| P value                                      |      | 0.46              |             |
| COVID-19 effect on family income/employment  |      |                   |             |
| No change                                    | 587  | Reference         | Reference   |
| Mild                                         | 554  | 1.46 (1.11–1.93)  | 1.42 (1.05–1.93) |
| Moderate                                     | 439  | 1.10 (0.83–1.46)  | 1.10 (0.79–1.52) |
| Severe                                       | 56   | 1.66 (0.82–3.38)  | 2.16 (0.95–4.93) |
| P value                                      |      | 0.04              | 0.05        |
| Census region                                |      |                   |             |
| Midwest                                      | 90   | 0.92 (0.56–1.52)  | N/A         |
| Northeast                                    | 142  | 0.94 (0.63–1.42)  |             |
| South                                        | 305  | 0.90 (0.67–1.20)  |             |
| West                                         | 1109 | Reference         | Reference   |
| P value                                      |      | 0.89              |             |
| Self-reported health, quintiles               |      |                   |             |
| Quintile 1 (lowest)                          | 345  | Reference         | Reference   |
| Quintile 2                                   | 264  | 0.68 (0.46–1.01)  | 0.59 (0.39–0.89) |
| Quintile 3                                   | 324  | 0.77 (0.53–1.12)  | 0.69 (0.46–1.02) |
| Quintile 4                                   | 351  | 0.65 (0.45–0.93)  | 0.63 (0.43–0.93) |
| Quintile 5 (highest)                         | 270  | 0.58 (0.40–0.85)  | 0.53 (0.36–0.80) |
| P value                                      |      | 0.06              | 0.03        |

1 Any vs. none (reference)
2 Native Hawaiian and Pacific Islanders
3 Ethnic Chinese includes mainland Chinese, Hongkonger, Taiwanese, and Huaren
4 English proficiency categorized as limited if speaking or reading or writing English was indicated as “some,” “a little” or “not at all”
5 SIP shelter-in-place
Thus, to have the vaccines manufactured and FDA approval provided all within the span of a year, even with strong evidence, has worried many [3]. Additionally, the study results suggested that distrust of government involvement in the trial and the politization of the vaccine were quite salient. This has been echoed in the USA and other countries’ data indicating distrust in ministries of health and/or institutions through which vaccine information is delivered influences its acceptance [35]. Finally, some participants had concerns that their own health conditions (e.g., egg allergy) would indicate contraindications with the vaccine [36]. While having concerns about potential side effects of the vaccine and/or additional concerns was common in this study sample, a sizable proportion of respondents who indicated “definitely” or “probably yes” to vaccine willingness also reported concerns about side effects and multiple concerns.

**Limitations**

There are several potential limitations. First, this study employed a cross-sectional convenient sample design with participants who self-identified AAPI. Findings may not be generalized to all AAPI. However, major demographic variables were measured and assessed, thus identifying important differences between categories. Nonetheless, this survey is among the first and largest survey targeting AAPI nationally yielding the findings that revealed subgroup differences in vaccine concerns. Future studies should confirm these findings in a more representative sample. These findings are important in informing policy and obtaining resources that require tailoring the different needs of the diverse AAPI population. Second, the study data were collected shortly before FDA authorized the first COVID-19 vaccine when efficacy and side effects of the vaccine remained unclear. As more people get vaccinated and the availability of new empirical data for vaccine safety and effectiveness, willingness and concerns of COVID-19 vaccine will likely be changed. This current study provides an important baseline before vaccine authorization to allow future investigation in changes over time.

**Conclusions**

COMPASS is one of the first national surveys targeting a large sample of AAPI to understand vaccination concerns and their correlates. AAPI is a diverse population, and this study revealed differences in vaccine concerns across AAPI groups. AAPI cultural group, age, gender, marital status, and health status are significant correlates of vaccine concerns, while nativity and LEP were not associated with vaccine concerns. The experience of negative impact on family income due to COVID-19 was also found to be associated with vaccine concerns but reasons remain unclear. Findings revealed potential targets for patient education needs. Effective strategies to address various vaccine concerns across subgroups of AAPI will be crucial to ensure equity in vaccination uptake.

**Acknowledgments** We want to acknowledge our community partners who have helped in the outreach and administration of COMPASS.

**Availability of Data and Materials** The COMPASS survey is currently ongoing. The datasets generated during and/or analyzed during the

---

**Table 4** Themes from open-ended responses

| Theme                                        | Quotes                                                                 |
|----------------------------------------------|------------------------------------------------------------------------|
| 1. Vaccine trial done too quickly           | “Afraid vaccine was rushed and not tested well”                        |
|                                              | “I am worried that the vaccine will make me sick because it’s being rushed and not given enough time for testing” |
| 2. Distrust of government involvement in     | “Distrust of the current political administration”                     |
| vaccine trial                                | “Concerned about rollout of vaccine being politically motivated and potentially at the expense of safety” |
| 3. Worry about side/long-term effects       | “I’d like to wait a couple years to watch for side effects and efficacy before I feel it may be safe to take the vaccine” |
|                                              | “Concern about long term effects that may not yet be known”            |
| 4. Concern about efficacy and               | “It may not be effective to prevent COVID”                             |
| effectiveness                                 | “Concerned it will require multiple injections, long-term efficacy”    |
| 5. Appropriateness for own body/self         | “Current pregnancy - worry vaccine won’t be safe during pregnancy”     |
|                                              | “I used to have an egg allergy and most vaccines are made of albumen (egg whites), so I generally have a localized allergic reaction to” |
|                                              | “I’m not sure that it will work on Pacific Islanders”                  |

1 There were 61 participants who provided text responses for other concerns that they had regarding COVID-19 vaccines
current study are available from the corresponding author on reasonable request.

**Code Availability** The SAS code used to produce these analyses is available upon request from the corresponding author.

**Funding** This study was supported by a COVID-19 administrative supplement grant from the National Institutes of Health/National Institute on Aging (3R24AG063718-02S1).

**Declarations**

**Conflict of Interest** The authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Kaiser Family Foundation. KFF COVID-19 vaccine monitor: December 2020. 2020. https://www.kff.org/coronavirus-covid-19/report/kff-covid-19-vaccine-monitor-december-2020/. Accessed January 9 2021.
2. Callaghan T, Moghaderi A, Lueck JA, Hotez PJ, Strych U, Dor A, et al. Correlates and disparities of COVID-19 vaccine hesitancy. 2020. https://doi.org/10.2139/ssrn.3667971.
3. Fisher KA, Bloomstone SJ, Walder J, Crawford S, Fouayzi H, Mazor KM. Attitudes toward a potential SARS-CoV-2 vaccine: a survey of U.S. adults. Ann Intern Med. 2020;173(12):964–73. https://doi.org/10.7326/M20-3569.
4. Kaiser Family Foundation. KFF COVID-19 vaccine monitor: what do we know about those who want to "wait and see" before getting a COVID-19 vaccine? 2021. https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-wait-and-see/. Accessed February 15 2021.
5. Fadda M, Albanese E, Suggs LS. When a COVID-19 vaccine is ready, will we all be ready for it? Int J Public Health. 2020;65(6):711–2. https://doi.org/10.1007/s00038-020-01404-4.
6. Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–73. https://doi.org/10.1056/NEJMmp2005630.
7. Pogue K, Jensen JL, Stancil CK, Ferguson DG, Hughes SJ, Mello EJ, et al. Influences on attitudes regarding potential COVID-19 vaccination in the United States. Vaccines (Basel). 2020;8(4). https://doi.org/10.3390/vaccines8040582.
8. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated? Vaccine. 2020;38(42):6500–7. https://doi.org/10.1016/j.vaccine.2020.08.043.
9. Neergaard L, Fingerhut H. AP-NORC poll: half of Americans would get a COVID-19 vaccine. Associated Press. 2020. https://journals.lww.com/ambulatorycaremanagement/fulltext/2021/01000/COVID_19_and_Vaccine_Hesitancy_A_Challenge_th.10.aspx?context=LatestArticles. Accessed February 15 2021.
10. Franklin Templeton-Gallup Economics of Recovery Study. Roundup of Recent Gallup Data on Vaccines. 2020. https://news.gallup.com/opinion/gallup/324527/roundup-recent-gallup-data-vaccines.aspx. Accessed January 10 2021.
11. Pew Research Center. Intent to get a COVID-19 vaccine rises to 60% as confidence in research and development process increases. 2020. https://www.pewresearch.org/science/2020/12/03/intent-to-get-a-covid-19-vaccine-rises-to-60-as-confidence-in-research-and-development-process-increases/. Accessed January 10 2021.
12. Chu JN, Tsol JY, Ong E, Ponce NA, The hidden colors of coronavirus: the burden of attributable COVID-19 deaths. J Gen Intern Med. 2021. https://doi.org/10.1007/s11606-020-06497-4.
13. Marcello RK, Dolle J, Tariq A, Kaur S, Wong L, Curcio J et al. Disaggregating Asian Race reveals COVID-19 disparities among Asian Americans at New York City’s Public Hospital System. 2020. https://doi.org/10.1101/2020.11.23.20233155.
14. Rubin-Miller L, Alban C, Artiga S, Sullivan S. COVID-19 racial disparities in testing, infection, hospitalization, and death: analysis of epic patient data. Kaiser Family Foundation. 2020. https://www.kff.org/coronavirus-covid-19/issue-brief/covid-19-racial-disparities-testing-infection-hospitalization-death-analysis-epic-patient-data/. Accessed January 11 2021.
15. U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine. 2021. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine. Accessed January 9 2021.
16. No Author. Collaborative approach for API research and education (CARE). 2021. https://careregistry.ucsf.edu/. Accessed January 9 2021.
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. https://doi.org/10.1016/j.jbi.2008.08.010.
18. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;55:103208. https://doi.org/10.1016/j.jbi.2019.103208.
19. Neumann-Bohme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, et al. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020;21(7):977–82. https://doi.org/10.1007/s10198-020-01208-4.
20. Johns Hopkins School of Medicine. Coronavirus Impact Scale. 2020. https://www.nlm.nih.gov/dr2/Coronavirus_Impact_Scale.pdf. Accessed April 28 2020.
21. Cawthon P, Orwell E, Ensrud K, Cauley JA, Kritchevsky SB, Cummings SR, et al. Assessing the impact of the covid-19 pandemic and accompanying mitigation efforts on older adults. J Gerontol A Biol Sci Med Sci. 2020;75:e123–5. https://doi.org/10.1093/gerona/glaa099.
22. Bureau USC. Census Regions and Divisions of the United States. Available at https://www.2census.gov/geopoly/data/maps-data/maps-reference/us_regdiv.pdf. Accessed January 29, 2021.
23. EuroQol G. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208. https://doi.org/10.1016/0168-8510(90)90421-9.
24. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43. https://doi.org/10.1080/03081090109002087.
25. World Health Organization. Process of translation and adaptation of instruments. 2018. http://www.who.int/substance_abuse/research_tools/translation/en/. Accessed September 11 2018.
26. U.S. Census Bureau. Language Use. 2019. https://www.census.gov/topics/population/language-use.html. Accessed January 31 2021.

27. Hosmer DW, Lemeshow S. Goodness of fit tests for the multiple logistic regression model. Commun Stat Theory Methods. 1980;9(10):1043–69. https://doi.org/10.1080/03610928008827941.

28. SAS Institute Inc. SAS® OnDemand for academics: user’s guide. Cary: SAS Institute Inc.; 2014.

29. Kahn C, Beasley D. More women than men in U.S. nervous about fast rollout of COVID vaccine, and that’s a problem: reuters/Ipsos poll. 2021. https://www.reuters.com/article/health-coronavirus-vaccine-poll/more-women-than-men-in-u-s-nervous-about-fast-rollout-of-covid-vaccine-and-thats-a-problem-reuters-ipsos-poll-idUSKBN28L0F3. Accessed March 5, 2021.

30. Centers for Disease Control and Prevention. Vaccination considerations for people who are pregnant or breastfeeding. 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html. Accessed March 3, 2021.

31. Ta Park VM, Dougan M, Meyer OL, Nam B, Tzuang M, Park LG et al. Vaccine willingness: findings from the COVID-19 effects on the mental and physical health of Asian Americans & Pacific Islanders Survey Study (COMPASS) (under review).

32. Ipsos. Global attitudes on a COVID-19 vaccine: Ipsos survey for the world economic forum. 2020. https://www.ipsos.com/sites/default/files/ct/news/documents/2020-12/global-attitudes-on-a-covid-19-vaccine-december-2020-report.pdf. Accessed February 7 2021.

33. Group C. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect Dis. 2020;20(7):769–70. https://doi.org/10.1016/S1473-3099(20)30426-6.

34. Larson HJ, Clarke RM, Jarrett C, Eckersberger E, Levine Z, Schulz WS, et al. Measuring trust in vaccination: a systematic review. Hum Vaccin Immunother. 2018;14(7):1599–609. https://doi.org/10.1080/21645515.2018.1459252.

35. Verger P, Scronias D, Dauby N, Adedzi KA, Gobert C, Bergeat M, et al. Attitudes of healthcare workers towards COVID-19 vaccination: a survey in France and French-speaking parts of Belgium and Canada, 2020. Euro Surveill. 2021;26(3). https://doi.org/10.2807/1560-7917.ES.2021.26.3.2002047.

36. Opri R, Zanoni G, Caffarelli C, Bottau P, Caimmi S, Crisafulli G, et al. True and false contraindications to vaccines. Allergol Immunopathol (Madrid). 2018;46(1):99–104. https://doi.org/10.1016/j.aller.2017.02.003.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.